Arvaya Healthcare Ltd
- Market cap
- ₹ 493 Cr.
- P/B
- 8.08x
- 52-week range
- 47.72 – 145
- Dividend yield
- 0%
- Debt / equity
- 0.82
- Sector
- Commercial Services & Supplies
- Industry
- Trading & Distributors
- Listed on
- BSE
About
Arvaya Healthcare Limited, formerly Bijoy Hans Limited, is an India-based company. The Company is mainly engaged in the business of trading in bulk drugs, pharmaceuticals, cosmetics and investment. The Company offers various pharmaceutical formulations, such as tablets, capsules, syrups, suspension and powders, focusing on segments, such as Antibiotics, Cough/ Cold/ Allergy. H-1 Receptor Antagonist (Antiulcerant), Nutraceuticals and NSAIDS.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Trading & Distributors: 197 companies →Arvaya Healthcare Ltd against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Share price, 3 months−20.5% against a typical −4.9%.143rd of 169
- Size₹ 493.4 Cr. market value against a typical ₹ 26.8 Cr. (1st = largest).14th of 183
Financials
Standalone figures in ₹ crore.
| ₹ Cr. | Jun 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|
| Sales | 0 | 911 | 2,991 |
| Expenses | 29 | 772 | 2,594 |
| Operating Profit | −29 | 139 | 397 |
| OPM % | — | 15% | 13% |
| Other Income | 3 | 130 | 19 |
| Interest | 0 | 41 | 139 |
| Depreciation | 0 | 62 | 220 |
| Profit before tax | −25 | 166 | 56 |
| Tax % | 0% | 11% | 5% |
| Net Profit | −25 | 147 | 53 |
| EPS in Rs | −33.72 | 26.37 | 8.01 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- —
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- —
- 10 Years
- —
- 5 Years
- 38%
- 3 Years
- 74%
- TTM
- —
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- —
Peers
Listed companies in the same business.
| Arvaya Healthcare Ltd | ₹ 108.95 | ₹ 493 Cr. | — | 8.1x | — | — |
| Aurobindo Pharma | ₹ 1,569.30 | ₹ 90,294 Cr. | 25.1x | 2.4x | 9.9% | 10.4% |
| Neuland Laboratories | ₹ 18,695.00 | ₹ 23,893 Cr. | 64.3x | 12.6x | 21.4% | 18% |
| Pfizer | ₹ 3,610.35 | ₹ 16,513 Cr. | 27.5x | 5x | 17.2% | 28.7% |
| Unichem Laboratories | ₹ 472.00 | ₹ 3,294 Cr. | 54.3x | 1.5x | 9.8% | 11.5% |
| Jagsonpal Pharmaceuticals | ₹ 213.00 | ₹ 1,402 Cr. | 34.3x | 5.4x | 16.7% | 15% |
Management
- Kaushal Uttam Shah
- Chairman of the Board, Managing Director
- Salil Sriram Shetty
- Chief Executive Officer, Executive Director
- Abhiram Ranganath
- Chief Financial Officer
- Guinea Agrawal
- Compliance Officer, Company Secretary
- Anilkumar Bidari Kotresh
- Additional Executive Director
Prices are delayed and for information only. Nothing on this page is investment advice.